"Antwort ID","Datum Abgeschickt","Letzte Seite","Start-Sprache","Zufallsstartwert","Zugangscode","Datum gestartet","Datum letzte Aktivität","IP-Adresse","Gesamtzeit","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ABCD1  Erkrankung: ABCD1-related adrenoleukodystrophy ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ABCD1  Erkrankung: ABCD1-related adrenoleukodystrophy [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ABCD1  Erkrankung: ABCD1-related adrenoleukodystrophy ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ABCD1  Erkrankung: ABCD1-related adrenoleukodystrophy [Kommentar]","Gruppenzeit: ABCD1","Fragenzeit: ABCD11","Fragenzeit: ABCD1B","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ACADM  Erkrankung: Medium chain acyl CoA dehydrogenase deficiency ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ACADM  Erkrankung: Medium chain acyl CoA dehydrogenase deficiency [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ACADM  Erkrankung: Medium chain acyl CoA dehydrogenase deficiency ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ACADM  Erkrankung: Medium chain acyl CoA dehydrogenase deficiency [Kommentar]","Gruppenzeit: ACADM","Fragenzeit: ACADM1","Fragenzeit: ACADMB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ACADVL  Erkrankung: VLCAD deficiency ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ACADVL  Erkrankung: VLCAD deficiency [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ACADVL  Erkrankung: VLCAD deficiency ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ACADVL  Erkrankung: VLCAD deficiency [Kommentar]","Gruppenzeit: ACADVL","Fragenzeit: ACADVL1","Fragenzeit: ACADVLB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ACAT1  Erkrankung: Alpha-methylacetoacetic aciduria ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ACAT1  Erkrankung: Alpha-methylacetoacetic aciduria [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ACAT1  Erkrankung: Alpha-methylacetoacetic aciduria ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ACAT1  Erkrankung: Alpha-methylacetoacetic aciduria [Kommentar]","Gruppenzeit: ACAT1","Fragenzeit: ACAT11","Fragenzeit: ACAT1B","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: AGL  Erkrankung: Glycogen Storage Disease Type III ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: AGL  Erkrankung: Glycogen Storage Disease Type III [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: AGL  Erkrankung: Glycogen Storage Disease Type III ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: AGL  Erkrankung: Glycogen Storage Disease Type III [Kommentar]","Gruppenzeit: AGL","Fragenzeit: AGL1","Fragenzeit: AGLB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: AGXT  Erkrankung: Primary hyperoxaluria type 1 ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: AGXT  Erkrankung: Primary hyperoxaluria type 1 [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: AGXT  Erkrankung: Primary hyperoxaluria type 1 ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: AGXT  Erkrankung: Primary hyperoxaluria type 1 [Kommentar]","Gruppenzeit: AGXT","Fragenzeit: AGXT1","Fragenzeit: AGXTB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ALDH7A1  Erkrankung: Pyridoxine-dependent epilepsy ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ALDH7A1  Erkrankung: Pyridoxine-dependent epilepsy [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ALDH7A1  Erkrankung: Pyridoxine-dependent epilepsy ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ALDH7A1  Erkrankung: Pyridoxine-dependent epilepsy [Kommentar]","Gruppenzeit: ALDH7A1","Fragenzeit: ALDH7A11","Fragenzeit: ALDH7A1B","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ALDOB  Erkrankung: hereditary fructose intolerance ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ALDOB  Erkrankung: hereditary fructose intolerance [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ALDOB  Erkrankung: hereditary fructose intolerance ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ALDOB  Erkrankung: hereditary fructose intolerance [Kommentar]","Gruppenzeit: ALDOB","Fragenzeit: ALDOB1","Fragenzeit: ALDOBB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ALPL  Erkrankung: ALPL-related autosomal recessive hypophosphatasia ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ALPL  Erkrankung: ALPL-related autosomal recessive hypophosphatasia [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ALPL  Erkrankung: ALPL-related autosomal recessive hypophosphatasia ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ALPL  Erkrankung: ALPL-related autosomal recessive hypophosphatasia [Kommentar]","Gruppenzeit: ALPL","Fragenzeit: ALPL1","Fragenzeit: ALPLB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ARG1  Erkrankung: arginase deficiency/Hyperargininemia ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ARG1  Erkrankung: arginase deficiency/Hyperargininemia [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ARG1  Erkrankung: arginase deficiency/Hyperargininemia ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ARG1  Erkrankung: arginase deficiency/Hyperargininemia [Kommentar]","Gruppenzeit: ARG1","Fragenzeit: ARG11","Fragenzeit: ARG1B","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ARSB  Erkrankung: mucopolysaccharidosis type 6 ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ARSB  Erkrankung: mucopolysaccharidosis type 6 [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ARSB  Erkrankung: mucopolysaccharidosis type 6 ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ARSB  Erkrankung: mucopolysaccharidosis type 6 [Kommentar]","Gruppenzeit: ARSB","Fragenzeit: ARSB1","Fragenzeit: ARSBB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ASL  Erkrankung: argininosuccinic aciduria ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ASL  Erkrankung: argininosuccinic aciduria [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ASL  Erkrankung: argininosuccinic aciduria ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ASL  Erkrankung: argininosuccinic aciduria [Kommentar]","Gruppenzeit: ASL","Fragenzeit: ASL1","Fragenzeit: ASLB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ASS1  Erkrankung: Citrullinemia ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ASS1  Erkrankung: Citrullinemia [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ASS1  Erkrankung: Citrullinemia ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ASS1  Erkrankung: Citrullinemia [Kommentar]","Gruppenzeit: ASS1","Fragenzeit: ASS11","Fragenzeit: ASS1B","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BCKDHA  Erkrankung: maple syrup urine disease ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BCKDHA  Erkrankung: maple syrup urine disease [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BCKDHA  Erkrankung: maple syrup urine disease ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BCKDHA  Erkrankung: maple syrup urine disease [Kommentar]","Gruppenzeit: BCKDHA","Fragenzeit: BCKDHA1","Fragenzeit: BCKDHAB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BCKDHB  Erkrankung: maple syrup urine disease ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BCKDHB  Erkrankung: maple syrup urine disease [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BCKDHB  Erkrankung: maple syrup urine disease ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BCKDHB  Erkrankung: maple syrup urine disease [Kommentar]","Gruppenzeit: BCKDHB","Fragenzeit: BCKDHB1","Fragenzeit: BCKDHBB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BCKDK  Erkrankung: branched-chain keto acid dehydrogenase kinase deficiency ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BCKDK  Erkrankung: branched-chain keto acid dehydrogenase kinase deficiency [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BCKDK  Erkrankung: branched-chain keto acid dehydrogenase kinase deficiency ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BCKDK  Erkrankung: branched-chain keto acid dehydrogenase kinase deficiency [Kommentar]","Gruppenzeit: BCKDK","Fragenzeit: BCKDK1","Fragenzeit: BCKDKB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BTD  Erkrankung: Biotinidase deficiency ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BTD  Erkrankung: Biotinidase deficiency [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BTD  Erkrankung: Biotinidase deficiency ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: BTD  Erkrankung: Biotinidase deficiency [Kommentar]","Gruppenzeit: BTD","Fragenzeit: BTD1","Fragenzeit: BTDB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CBS  Erkrankung: classis homocystinuria ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CBS  Erkrankung: classis homocystinuria [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CBS  Erkrankung: classis homocystinuria ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CBS  Erkrankung: classis homocystinuria [Kommentar]","Gruppenzeit: CBS","Fragenzeit: CBS1","Fragenzeit: CBSB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CPS1  Erkrankung: carbamoyl phosphate synthetase I deficiency disease ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CPS1  Erkrankung: carbamoyl phosphate synthetase I deficiency disease [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CPS1  Erkrankung: carbamoyl phosphate synthetase I deficiency disease ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CPS1  Erkrankung: carbamoyl phosphate synthetase I deficiency disease [Kommentar]","Gruppenzeit: CPS1","Fragenzeit: CPS11","Fragenzeit: CPS1B","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CPT1A  Erkrankung: carnitine palmitoyl transferase 1A deficiency ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CPT1A  Erkrankung: carnitine palmitoyl transferase 1A deficiency [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CPT1A  Erkrankung: carnitine palmitoyl transferase 1A deficiency ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CPT1A  Erkrankung: carnitine palmitoyl transferase 1A deficiency [Kommentar]","Gruppenzeit: CPT1A","Fragenzeit: CPT1A1","Fragenzeit: CPT1AB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CPT2  Erkrankung: carnitine palmitoyltransferase II deficiency ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CPT2  Erkrankung: carnitine palmitoyltransferase II deficiency [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CPT2  Erkrankung: carnitine palmitoyltransferase II deficiency ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CPT2  Erkrankung: carnitine palmitoyltransferase II deficiency [Kommentar]","Gruppenzeit: CPT2","Fragenzeit: CPT21","Fragenzeit: CPT2B","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CTNS  Erkrankung: cystinosis ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CTNS  Erkrankung: cystinosis [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CTNS  Erkrankung: cystinosis ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: CTNS  Erkrankung: cystinosis [Kommentar]","Gruppenzeit: CTNS","Fragenzeit: CTNS1","Fragenzeit: CTNSB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: DBT  Erkrankung: maple syrup urine disease type II ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: DBT  Erkrankung: maple syrup urine disease type II [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: DBT  Erkrankung: maple syrup urine disease type II ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: DBT  Erkrankung: maple syrup urine disease type II [Kommentar]","Gruppenzeit: DBT","Fragenzeit: DBT1","Fragenzeit: DBTB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ETFB  Erkrankung: multiple acyl-CoA dehydrogenase deficiency (glutaric aciduria II) ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ETFB  Erkrankung: multiple acyl-CoA dehydrogenase deficiency (glutaric aciduria II) [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ETFB  Erkrankung: multiple acyl-CoA dehydrogenase deficiency (glutaric aciduria II) ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ETFB  Erkrankung: multiple acyl-CoA dehydrogenase deficiency (glutaric aciduria II) [Kommentar]","Gruppenzeit: ETFB","Fragenzeit: ETFB1","Fragenzeit: ETFBB","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ETFDH  Erkrankung: multiple acyl-CoA dehydrogenase deficiency (glutaric aciduria II) ","Sollte folgendes Gen / Ekrankung in einem nationalen genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ETFDH  Erkrankung: multiple acyl-CoA dehydrogenase deficiency (glutaric aciduria II) [Kommentar]","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ETFDH  Erkrankung: multiple acyl-CoA dehydrogenase deficiency (glutaric aciduria II) ","Sollte folgendes Gen / Ekrankung im Rahmen wissenschaftlicher Studien zum genomischen Neugeborenenscreening berücksichtigt werden?  Gen: ETFDH  Erkrankung: multiple acyl-CoA dehydrogenase deficiency (glutaric aciduria II) [Kommentar]","Gruppenzeit: ETFDH","Fragenzeit: ETFDH1","Fragenzeit: ETFDHB"
"1","2026-02-10 8:35:00","25","de","508830029","","2026-02-10 7:06:00","2026-02-10 8:49:00","192.168.46.59","611.48","Nein","X-chromosomal, daher v.a. Knaben betroffen – gute Begründung für NBS","Ja","Gentherapie-Studien laufen – Timing der NBS-Einführung wichtig","46.59","18.6","25.69","Ja","","Ja","","37.99","28.25","8.63","Ja","","Ja","","85.48","22.56","31.66","Ja","","Ja","","27.9","3.28","10.54","Ich kann diese Frage nicht beantworten","Keine kurative Therapie verfügbar","Ja","","88.02","16.23","10.99","Ich kann diese Frage nicht beantworten","","Ja","","88.55","37.92","27.43","Ja","","Ja","","11.9","18.74","6.18","Ja","","Ja","","22.07","32.13","5.05","Ja","","Ja","","69.92","16.09","28.71","Ich kann diese Frage nicht beantworten","","Ja","","68.51","25.5","18.11","Ja","ERT verfügbar, Frühdiagnose sinnvoll","Ja","","83.55","35.58","14.81","Ja","","Ja","","77.92","16.38","28.1","Ja","","Ja","","33.68","16.95","15.46","Ja","","Ja","","50.42","9.71","4.39","Ja","","Ja","","24.57","34.58","11.36","Nein","","Ja","","69.94","29.33","29.33","Ja","","Ja","","80.01","18.58","36.58","Ja","","Ja","","32.25","20.65","7.71","Ich kann diese Frage nicht beantworten","NBS-Nutzen fraglich bei schwerem Verlauf","Ja","","18.55","17.02","28.1","Nein","","Ja","","21.53","15.46","10.31","Ja","","Ja","","80.76","27.71","32.21","Ja","","Ja","","39.7","34.88","27.29","Ja","","Ja","","49.38","38.15","39.2","Ich kann diese Frage nicht beantworten","","Ja","","27.43","34.5","18.42","Nein","","Ja","","56.5","13.64","30.35"
"2","2026-02-10 9:16:00","25","de","965840373","","2026-02-10 8:09:00","2026-02-10 9:32:00","192.168.149.9","1074.74","Ja","","Ja","","54.98","13.92","31.0","Ich kann diese Frage nicht beantworten","Diättherapie effektiv und gut etabliert","Ja","","27.51","15.18","35.48","Nein","","Ja","","38.07","23.79","29.46","Ja","","Ja","","44.37","34.24","28.89","Ja","","Ich kann diese Frage nicht beantworten","","58.2","36.89","27.61","Ich kann diese Frage nicht beantworten","","Ja","","14.76","32.46","5.67","Ja","","Ja","","6.02","14.81","12.68","Ja","","Ich kann diese Frage nicht beantworten","NBS-Pilotprojekt könnte Datenlage verbessern","52.2","13.81","34.0","Ja","","Ja","","21.02","20.93","13.09","Nein","","Ja","","19.76","16.09","38.52","Nein","ERT verfügbar, Frühdiagnose sinnvoll","Nein","","17.77","6.2","31.09","Ja","","Ja","","65.94","25.75","31.14","Ja","Bereits in NBS vieler Länder","Ja","","73.8","19.14","14.38","Ja","","Ja","","49.31","37.4","11.55","Nein","","Ja","","89.14","23.97","30.12","Nein","","Ich kann diese Frage nicht beantworten","Registerstudie dringend empfohlen","70.79","16.81","14.6","Ja","","Ja","","18.5","37.91","35.6","Ja","Gut etabliertes NBS-Gen","Ja","","73.14","4.49","9.07","Nein","","Nein","","87.34","16.94","13.01","Ja","","Ja","","69.91","37.74","30.34","Ja","","Ja","","39.53","5.02","11.95","Ja","Cysteamin-Therapie sehr effektiv wenn früh begonnen","Ja","","7.44","10.48","36.32","Ja","","Ja","","26.64","24.45","18.93","Ja","","Ja","","88.02","5.74","24.76","Ja","","Ja","Riboflavin-Response prospektiv erfassen","24.77","24.2","10.71"
"3","2026-02-11 10:16:00","25","de","568512911","","2026-02-11 9:19:00","2026-02-11 10:36:00","192.168.232.205","562.83","Nein","Frühzeitige Diagnose würde klinisch relevant sein","Nein","Gentherapie-Studien laufen – Timing der NBS-Einführung wichtig","62.14","21.67","35.21","Ja","","Ja","","63.4","18.58","22.4","Ja","","Ja","","33.41","10.0","32.36","Ja","","Ja","","10.28","10.02","4.85","Ja","","Ja","","54.07","13.93","29.85","Ja","Datenlage noch unvollständig","Ja","","21.84","5.06","38.46","Ja","Gute Behandelbarkeit spricht für NBS","Ja","Outcome-Daten unter früher Pyridoxin-Therapie sammeln","80.64","12.06","8.68","Ja","","Ja","","26.75","37.83","26.87","Ja","Milde Verlaufsformen würden zu Überdiagnose führen","Ja","","36.43","18.68","35.41","Nein","Outcome unter Therapie enttäuschend","Ich kann diese Frage nicht beantworten","","28.23","12.01","37.42","Ja","Langzeitdaten zur ERT noch begrenzt","Ja","","25.66","19.36","19.45","Ja","Gut etabliertes NBS-Gen","Ja","","15.37","3.65","21.28","Nein","Bereits in NBS vieler Länder","Ja","","48.32","11.7","28.67","Nein","","Ja","","38.86","10.71","24.87","Ja","","Ja","","55.61","28.77","4.76","Ja","","Ja","","61.36","24.69","3.66","Ja","","Ja","","59.41","6.96","39.9","Ja","Behandelbar mit B6 und Homocystin-armer Diät","Ja","","74.61","28.56","39.94","Nein","","Ja","","37.82","6.56","12.95","Ja","","Ja","","18.46","13.14","7.57","Nein","Milde Verlaufsformen dominieren","Nein","Phänotypische Heterogenität in Studie besser charakterisieren","55.81","11.05","39.88","Nein","Klares Argument für NBS","Ja","","20.67","13.48","10.04","Ja","","Ja","","35.18","22.09","11.39","Ja","Schwere neonatale Form nicht behandelbar","Ja","","12.0","18.62","18.75","Ja","","Ja","Riboflavin-Response prospektiv erfassen","30.39","7.24","30.06"
"4","2026-02-11 11:55:00","25","de","433403086","","2026-02-11 10:05:00","2026-02-11 11:56:00","192.168.143.174","866.75","Ja","Therapieoption vorhanden, aber Datenlage dünn","Ja","","33.46","4.58","27.0","Ja","","Ja","","34.59","4.59","15.03","Nein","","Nein","","77.32","33.01","26.24","Ja","","Ja","","86.65","25.34","23.62","Nein","Phänotypische Variabilität sehr hoch","Nein","Registerstudie sinnvoll","17.99","19.14","5.53","Ja","","Ja","","52.05","28.64","31.6","Ja","Gute Behandelbarkeit spricht für NBS","Ja","","59.04","4.49","26.26","Nein","Symptomatik tritt meist erst bei Nahrungseinführung auf – NBS-Zeitfenster fraglich","Ja","","59.53","37.12","12.58","Nein","Enzymersatztherapie verfügbar (Asfotase alfa)","Ich kann diese Frage nicht beantworten","","27.25","6.65","3.17","Nein","","Ja","","88.02","39.78","13.22","Ich kann diese Frage nicht beantworten","","Ja","","29.41","28.96","31.98","Ja","","Ja","","27.29","12.14","22.37","Ja","","Ja","","12.86","38.69","4.09","Ja","MSUD-Diät effektiv wenn früh begonnen","Ja","","25.54","21.78","4.4","Ja","","Ja","","52.73","7.77","26.79","Ich kann diese Frage nicht beantworten","Late-Onset-Formen unklar","Nein","Registerstudie dringend empfohlen","66.57","37.49","19.69","Ja","","Ja","","66.05","11.02","4.65","Ja","","Ich kann diese Frage nicht beantworten","","80.49","38.9","36.92","Ja","","Ja","","66.4","4.21","5.09","Ja","","Ja","","36.57","31.11","31.28","Ja","","Ja","","7.71","15.2","33.47","Nein","Klares Argument für NBS","Ja","","48.56","20.71","5.94","Ja","","Ja","","56.51","20.74","23.6","Nein","Stark variable Phänotypen erschweren Bewertung","Ja","","79.55","29.35","3.66","Ja","","Ja","","39.09","35.72","16.86"
"5","2026-02-12 12:20:00","25","de","106493659","","2026-02-12 11:04:00","2026-02-12 12:47:00","192.168.119.119","630.46","Nein","","Ja","","53.18","28.56","4.79","Ja","Sehr gute Behandelbarkeit rechtfertigt Aufnahme","Ja","","23.02","7.36","28.44","Ich kann diese Frage nicht beantworten","Gut behandelbar mit diätetischen Maßnahmen","Ja","","88.08","29.05","6.31","Ich kann diese Frage nicht beantworten","","Ja","","72.55","17.31","38.97","Nein","Phänotypische Variabilität sehr hoch","Ich kann diese Frage nicht beantworten","Studien zu Therapieoptionen abwarten","12.32","20.42","10.97","Ich kann diese Frage nicht beantworten","Nierentransplantation als Option, Frühdiagnose hilfreich","Ja","","89.36","18.86","35.27","Ja","","Ja","","17.19","24.04","28.57","Ja","","Ja","","63.36","21.03","25.04","Ja","","Ja","","46.13","38.7","36.39","Nein","Späte klinische Manifestation relativiert NBS-Nutzen","Ja","","85.46","33.65","29.98","Ja","","Nein","","85.89","37.42","39.67","Ja","","Ja","","16.38","11.17","31.45","Ja","Diät und Arginin-Supplementation effektiv","Ja","","70.19","4.44","11.13","Ja","","Ja","","5.55","20.07","20.62","Ja","","Ja","","25.73","3.64","19.72","Ja","","Ich kann diese Frage nicht beantworten","","23.15","35.37","36.82","Ja","","Ja","","20.83","28.03","15.37","Ja","","Ja","","6.24","4.06","22.83","Ja","","Ja","","65.5","37.18","28.53","Ich kann diese Frage nicht beantworten","Ethnische Häufung in bestimmten Populationen","Ja","","55.11","27.94","38.5","Ich kann diese Frage nicht beantworten","","Nein","Phänotypische Heterogenität in Studie besser charakterisieren","56.26","11.54","14.42","Ich kann diese Frage nicht beantworten","Frühdiagnose entscheidend für Nierenfunktion","Ja","Frühtherapie-Studien unterstützen NBS-Entscheidung klar","62.87","7.12","17.38","Ja","","Ja","","76.21","23.47","32.71","Ja","Schwere neonatale Form nicht behandelbar","Nein","Genotyp-basierte Stratifizierung in Studie prüfen","27.83","30.2","9.62","Ich kann diese Frage nicht beantworten","","Ja","Riboflavin-Response prospektiv erfassen","18.2","14.29","16.08"
"6","2026-02-12 13:19:00","25","de","164129306","","2026-02-12 12:04:00","2026-02-12 13:39:00","192.168.167.91","825.9","Ja","Frühzeitige Diagnose würde klinisch relevant sein","Nein","Studienlage sollte erst verbessert werden","75.11","6.1","23.71","Ja","Sehr gute Behandelbarkeit rechtfertigt Aufnahme","Ja","","37.68","8.17","25.79","Ich kann diese Frage nicht beantworten","Gut behandelbar mit diätetischen Maßnahmen","Ja","","74.29","19.78","18.4","Nein","","Ja","","85.04","35.88","13.41","Ja","","Ja","","67.62","6.72","29.03","Ja","Datenlage noch unvollständig","Ja","Lumasiran-Studien abwarten","19.44","12.21","7.56","Ja","","Ja","","79.29","16.74","16.86","Nein","Symptomatik tritt meist erst bei Nahrungseinführung auf – NBS-Zeitfenster fraglich","Nein","Kostenevaluation notwendig","32.25","5.82","9.44","Ja","","Ja","","59.21","27.85","4.65","Nein","Späte klinische Manifestation relativiert NBS-Nutzen","Nein","Vergleich mit symptomatisch diagnostizierten Patienten fehlt","68.33","7.58","9.05","Nein","ERT verfügbar, Frühdiagnose sinnvoll","Nein","Studieneinschluss sinnvoll","76.67","24.75","38.16","Ja","","Ja","","48.99","37.38","3.67","Ja","","Ja","","28.02","24.36","12.39","Ja","","Ja","","44.5","15.74","39.2","Ja","","Ja","","78.78","35.52","5.53","Ich kann diese Frage nicht beantworten","","Ja","","49.89","22.37","18.51","Ja","","Ja","","20.79","16.37","36.5","Ja","","Ja","","68.47","16.37","38.12","Nein","","Ja","","19.31","16.79","11.97","Ja","","Ja","","55.41","30.07","20.85","Ja","","Ja","","78.38","9.4","37.23","Ja","","Ja","Frühtherapie-Studien unterstützen NBS-Entscheidung klar","6.21","37.66","30.87","Ja","MSUD-assoziiert, konsistente Bewertung sinnvoll","Ja","","69.7","34.3","25.41","Ja","","Ja","","13.75","6.87","35.55","Ja","","Ja","","79.57","30.45","39.8"
"7","2026-02-13 14:49:00","25","de","190017205","","2026-02-13 13:14:00","2026-02-13 14:48:00","192.168.221.151","837.77","Ja","","Ja","Studienlage sollte erst verbessert werden","72.17","30.62","29.13","Ja","","Ja","","45.55","4.64","11.08","Ja","","Ja","","77.39","5.11","10.64","Ja","","Ja","","50.29","28.5","8.42","Nein","","Nein","Studien zu Therapieoptionen abwarten","75.4","32.04","8.34","Nein","Nierentransplantation als Option, Frühdiagnose hilfreich","Nein","","45.22","34.95","32.36","Ja","","Ja","","19.52","8.03","11.54","Nein","","Ja","","34.81","25.97","4.7","Ja","Milde Verlaufsformen würden zu Überdiagnose führen","Ja","","79.54","22.66","27.96","Ich kann diese Frage nicht beantworten","","Ja","","6.57","11.32","12.18","Nein","","Ja","","60.27","36.56","27.36","Ja","","Ja","","45.74","30.92","18.27","Ja","","Ja","","5.86","14.67","14.88","Ja","","Ja","","44.09","26.1","17.46","Ja","","Ja","","7.37","33.48","38.81","Nein","","Ja","","74.72","20.14","34.56","Ja","Biotin-Therapie einfach und hochwirksam","Ja","","83.26","16.94","4.35","Ja","","Ja","","55.18","17.67","10.46","Nein","Outcome trotz Therapie oft schlecht","Ja","","45.39","7.34","21.5","Ja","","Ja","","89.9","38.88","5.16","Ja","","Ja","","82.95","8.05","8.28","Ja","","Ja","","53.15","34.64","6.56","Ja","","Ja","","9.48","16.69","26.89","Ja","","Ja","Genotyp-basierte Stratifizierung in Studie prüfen","34.06","19.1","34.24","Nein","","Ja","","70.26","5.49","24.38"
"8","2026-02-13 15:20:00","25","de","762400249","","2026-02-13 14:28:00","2026-02-13 15:34:00","192.168.196.28","976.17","Nein","Frühzeitige Diagnose würde klinisch relevant sein","Ja","","17.6","5.88","27.29","Ja","","Ja","","42.15","6.91","21.67","Nein","Frühzeitige Diagnose verhindert metabolische Krisen","Ja","","74.55","16.37","6.79","Ich kann diese Frage nicht beantworten","","Ja","","76.5","5.64","35.54","Ich kann diese Frage nicht beantworten","","Nein","Registerstudie sinnvoll","80.66","31.58","34.92","Ja","","Ja","Lumasiran-Studien abwarten","34.27","19.56","11.03","Ja","","Ja","","21.8","25.35","14.42","Nein","Niedrige Prävalenz, Kosten-Nutzen unklar","Nein","Kostenevaluation notwendig","26.55","11.88","14.26","Ja","Schwere Verlaufsformen gut behandelbar","Ja","","72.69","24.14","24.36","Ja","","Ja","","9.1","4.71","32.77","Ja","","Ich kann diese Frage nicht beantworten","","21.37","11.27","18.55","Ja","","Ja","","24.87","33.63","15.45","Ja","Diät und Arginin-Supplementation effektiv","Ja","","82.95","27.52","9.74","Ja","","Nein","","65.75","12.24","19.34","Ja","","Ja","","43.1","17.17","31.6","Nein","","Ja","","49.21","30.05","28.84","Ja","","Ja","","83.63","18.47","27.56","Ja","","Ja","","30.91","10.52","9.45","Ja","","Ja","","21.45","19.6","34.15","Ja","Ethnische Häufung in bestimmten Populationen","Ja","","55.5","11.57","4.01","Ja","","Ja","","14.1","14.69","22.33","Nein","Frühdiagnose entscheidend für Nierenfunktion","Ja","","38.44","6.61","20.04","Nein","Wie BCKDHA zu bewerten","Ja","","17.38","22.71","37.56","Ja","Stark variable Phänotypen erschweren Bewertung","Ich kann diese Frage nicht beantworten","","70.02","3.95","15.54","Ja","","Ja","","82.59","35.91","26.14"
"9","2026-02-14 8:30:00","25","de","410199505","","2026-02-14 7:12:00","2026-02-14 8:38:00","192.168.227.137","506.21","Ja","","Ja","","52.45","6.88","16.12","Ja","","Ja","","10.59","9.85","20.49","Ja","","Ja","","42.11","24.73","12.64","Nein","","Ja","","89.07","21.24","36.94","Ja","","Nein","Registerstudie sinnvoll","8.5","39.35","24.45","Ja","","Ja","","37.64","22.89","8.38","Nein","Pyridoxin-Therapie effektiv wenn früh begonnen","Ja","","71.97","3.03","12.63","Ich kann diese Frage nicht beantworten","Symptomatik tritt meist erst bei Nahrungseinführung auf – NBS-Zeitfenster fraglich","Ja","","32.44","28.6","11.37","Ja","","Ja","","54.92","22.08","29.29","Ja","Neurologische Schäden trotz Therapie häufig","Ich kann diese Frage nicht beantworten","Studiendaten zum Outcome unter NBS notwendig","43.8","7.13","17.52","Nein","","Nein","","77.26","17.49","39.43","Ja","Klare Behandelbarkeit mit Arginin-Supplementation","Ja","","53.47","17.39","5.11","Nein","","Ja","","64.25","34.21","26.01","Ja","","Ja","","18.03","14.17","9.42","Ja","","Ja","","36.9","13.13","10.37","Nein","Late-Onset-Formen unklar","Ich kann diese Frage nicht beantworten","Registerstudie dringend empfohlen","40.2","29.13","3.99","Ja","","Ja","","38.55","9.99","7.94","Ja","","Ja","","13.13","15.95","34.03","Ja","","Ja","","38.45","25.58","37.2","Nein","Datenlage gut für bestimmte Mutationen","Ja","","72.37","10.71","33.87","Ja","","Ja","Phänotypische Heterogenität in Studie besser charakterisieren","26.27","10.02","11.0","Nein","Klares Argument für NBS","Ja","","46.25","12.02","18.98","Ja","","Ja","","17.82","36.52","35.21","Nein","Schwere neonatale Form nicht behandelbar","Ja","Genotyp-basierte Stratifizierung in Studie prüfen","61.6","37.39","31.27","Nein","","Nein","Riboflavin-Response prospektiv erfassen","44.02","10.4","20.2"
"10","2026-02-14 9:17:00","25","de","345711342","","2026-02-14 8:22:00","2026-02-14 9:53:00","192.168.138.210","736.16","Ich kann diese Frage nicht beantworten","Frühzeitige Diagnose würde klinisch relevant sein","Ja","","14.53","34.76","15.16","Ja","","Ja","","67.0","18.4","12.25","Ja","","Ja","","10.88","5.72","30.17","Ja","","Ja","","32.08","38.75","26.83","Ich kann diese Frage nicht beantworten","Keine kurative Therapie verfügbar","Ich kann diese Frage nicht beantworten","","25.39","4.53","20.78","Ich kann diese Frage nicht beantworten","Datenlage noch unvollständig","Ja","","21.22","28.86","27.46","Ja","","Ja","","42.74","19.51","29.99","Nein","","Nein","","6.42","39.42","17.26","Ja","","Ja","","36.78","4.57","18.89","Ja","Outcome unter Therapie enttäuschend","Ja","","57.68","17.8","8.01","Ja","Langzeitdaten zur ERT noch begrenzt","Ja","","82.74","19.19","9.31","Nein","Klare Behandelbarkeit mit Arginin-Supplementation","Ja","","17.62","37.05","30.63","Ja","","Ja","","14.38","14.55","16.01","Ja","","Ja","","89.92","12.93","26.1","Ja","","Ja","","70.53","10.86","23.07","Ich kann diese Frage nicht beantworten","","Nein","Internationale Kollaboration notwendig","46.7","7.08","4.99","Ja","","Ja","","28.89","31.32","6.45","Ja","","Ja","","89.33","35.93","34.48","Ja","","Ja","Lebertransplantations-Outcome unter NBS-Bedingungen prüfen","75.52","37.88","4.15","Nein","","Ja","","49.74","8.44","16.35","Nein","Klinisch heterogen, schwere neonatale Form selten","Ja","","34.1","17.33","20.76","Ja","","Ja","","46.33","11.77","28.0","Ja","","Ja","","5.91","22.26","39.61","Ich kann diese Frage nicht beantworten","Schwere neonatale Form nicht behandelbar","Nein","","83.19","26.96","26.71","Nein","Riboflavin-responsive Formen behandelbar","Ja","","41.72","29.4","9.97"
"11","2026-02-15 10:10:00","25","de","653380805","","2026-02-15 9:30:00","2026-02-15 10:41:00","192.168.24.86","986.5","Ja","","Ja","","30.49","24.44","27.62","Ja","","Ja","","55.37","28.0","11.69","Nein","Frühzeitige Diagnose verhindert metabolische Krisen","Ja","","38.73","33.39","13.68","Nein","","Ja","","77.01","18.43","19.23","Nein","","Nein","","24.03","32.7","30.33","Ja","","Ja","","69.78","20.37","18.38","Ja","","Ja","","39.42","19.16","39.13","Ja","","Ich kann diese Frage nicht beantworten","NBS-Pilotprojekt könnte Datenlage verbessern","86.31","32.57","34.49","Ja","","Ja","","18.27","35.16","32.76","Nein","","Ja","","86.69","36.98","26.99","Nein","Multisystemerkrankung mit gutem Therapieansprechen","Ja","","15.1","23.92","13.03","Ja","","Ja","","26.58","15.87","3.83","Ja","Diät und Arginin-Supplementation effektiv","Ja","","88.31","35.18","37.62","Ja","","Nein","","53.56","22.25","25.64","Ja","","Ja","","31.94","7.94","18.73","Nein","Genetische Heterogenität erschwert Interpretation","Ja","","47.13","16.67","36.33","Ja","Biotin-Therapie einfach und hochwirksam","Ja","","39.22","6.19","28.28","Ja","","Ja","","69.81","22.49","34.9","Nein","","Ja","","40.51","16.48","18.74","Ja","","Ja","","73.53","11.11","25.36","Ja","","Nein","","65.18","13.83","35.85","Nein","","Ja","Frühtherapie-Studien unterstützen NBS-Entscheidung klar","26.14","17.89","6.89","Nein","Wie BCKDHA zu bewerten","Ja","","85.65","19.99","28.46","Ja","","Nein","Genotyp-basierte Stratifizierung in Studie prüfen","45.03","32.3","8.81","Ja","","Ja","","66.14","15.09","20.9"
"12","2026-02-15 11:27:00","25","de","452304670","","2026-02-15 10:14:00","2026-02-15 11:34:00","192.168.168.128","874.05","Ja","","Ja","","69.61","6.24","27.65","Ja","","Ja","","25.13","13.89","22.39","Nein","Gut behandelbar mit diätetischen Maßnahmen","Ja","","8.89","28.6","31.2","Ja","","Ja","","75.6","33.87","33.63","Nein","","Ja","","88.48","5.34","6.9","Ja","","Nein","Studiendaten zur Frühtherapie fehlen noch","70.82","34.03","15.33","Ja","","Ja","","8.42","4.93","23.75","Nein","","Ja","","58.21","34.09","25.22","Ja","","Ja","","57.27","39.23","11.25","Nein","","Ja","","34.44","7.31","27.37","Nein","Langzeitdaten zur ERT noch begrenzt","Ja","Studieneinschluss sinnvoll","58.88","28.95","30.87","Ja","","Ja","","56.15","19.67","31.85","Nein","","Ja","","63.46","8.21","28.38","Ja","Lebertransplantation als kurative Option","Ja","","11.73","17.72","28.96","Ja","","Ja","","74.06","28.8","28.92","Nein","Genetische Heterogenität erschwert Interpretation","Nein","","15.03","38.21","27.97","Ja","","Ja","","65.44","32.23","18.9","Ja","","Ja","","52.27","32.3","37.54","Ja","","Ja","","40.28","6.61","32.67","Ja","","Ja","","23.63","27.15","13.13","Ja","Klinisch heterogen, schwere neonatale Form selten","Ja","","52.5","19.24","3.22","Ja","","Ja","Frühtherapie-Studien unterstützen NBS-Entscheidung klar","60.84","25.66","17.91","Ja","","Ja","","81.58","26.42","25.62","Ja","","Ja","","25.08","32.98","33.69","Ich kann diese Frage nicht beantworten","Riboflavin-responsive Formen behandelbar","Ja","","64.23","27.61","5.08"
"13","2026-02-16 12:12:00","25","de","912812658","","2026-02-16 11:09:00","2026-02-16 12:56:00","192.168.45.159","1078.64","Nein","Genotyp-Phänotyp-Korrelation unzureichend","Ich kann diese Frage nicht beantworten","","20.02","16.44","35.16","Ja","Sehr gute Behandelbarkeit rechtfertigt Aufnahme","Ja","","63.96","27.89","19.27","Ja","Evidenzlage überzeugend","Ja","","70.11","8.91","27.59","Ja","","Ja","","86.14","5.42","26.11","Ja","","Ja","","42.68","24.45","31.25","Ja","Datenlage noch unvollständig","Ja","","69.08","4.91","39.2","Ja","","Ja","","47.9","28.45","36.53","Ich kann diese Frage nicht beantworten","Diät einfach und effektiv, aber Diagnose oft klinisch möglich","Ja","Kostenevaluation notwendig","42.49","17.44","10.92","Ja","Enzymersatztherapie verfügbar (Asfotase alfa)","Ja","","58.75","22.86","9.58","Ja","Neurologische Schäden trotz Therapie häufig","Ja","","21.38","32.02","7.21","Ich kann diese Frage nicht beantworten","","Ja","","40.08","3.51","28.68","Ja","","Ja","","50.15","22.04","39.99","Ja","","Ja","","47.73","34.56","3.86","Ja","","Nein","","31.75","29.51","38.08","Ja","","Ja","","6.6","37.76","11.04","Ich kann diese Frage nicht beantworten","","Nein","","36.78","4.55","34.81","Ja","","Ja","","51.26","38.37","8.91","Ja","","Ja","","85.59","21.39","37.62","Ja","","Ja","","23.3","31.5","32.51","Ja","Datenlage gut für bestimmte Mutationen","Ja","","65.78","26.95","28.74","Ja","Milde Verlaufsformen dominieren","Ja","","19.51","33.99","32.5","Ich kann diese Frage nicht beantworten","Frühdiagnose entscheidend für Nierenfunktion","Ja","","56.61","20.72","32.24","Nein","Wie BCKDHA zu bewerten","Ja","","43.85","7.15","39.46","Ja","","Ja","","63.27","17.89","4.53","Nein","Riboflavin-responsive Formen behandelbar","Ja","","34.95","34.25","17.28"
"14","2026-02-16 13:44:00","25","de","414812120","","2026-02-16 12:20:00","2026-02-16 13:57:00","192.168.80.93","610.76","Nein","Frühzeitige Diagnose würde klinisch relevant sein","Ja","Prospektive Studie würde Evidenz stärken","47.18","17.76","28.66","Ja","Sehr gute Behandelbarkeit rechtfertigt Aufnahme","Ja","","28.69","15.98","30.53","Ja","","Ja","","29.82","14.22","19.76","Ja","","Ja","","6.61","34.98","11.23","Ja","","Ja","","37.03","13.3","7.69","Ich kann diese Frage nicht beantworten","Nierentransplantation als Option, Frühdiagnose hilfreich","Ja","","71.08","35.84","33.34","Ja","Klinisches Bild variabel","Ja","","76.07","31.45","24.16","Nein","","Ich kann diese Frage nicht beantworten","","82.18","27.78","24.01","Nein","","Ja","","42.22","31.8","10.57","Ja","Neurologische Schäden trotz Therapie häufig","Ja","","14.31","39.59","35.06","Ich kann diese Frage nicht beantworten","","Ja","","85.72","37.93","35.34","Ja","","Ja","","72.17","6.26","28.69","Ja","","Nein","","39.04","33.23","21.37","Ja","","Ja","","14.89","22.11","22.18","Ja","","Ja","","54.27","32.45","20.07","Ich kann diese Frage nicht beantworten","Late-Onset-Formen unklar","Ja","","19.83","24.59","11.87","Ja","","Ja","","57.49","13.71","9.36","Ja","","Ja","","34.07","17.52","8.58","Nein","","Ja","Lebertransplantations-Outcome unter NBS-Bedingungen prüfen","86.7","26.51","8.03","Ja","","Nein","","13.05","26.86","12.37","Ich kann diese Frage nicht beantworten","","Ja","","86.51","14.12","13.49","Ja","","Nein","Frühtherapie-Studien unterstützen NBS-Entscheidung klar","17.43","15.66","22.76","Ja","","Ja","","70.67","32.15","32.21","Ja","","Ich kann diese Frage nicht beantworten","Genotyp-basierte Stratifizierung in Studie prüfen","21.1","14.33","14.8","Ja","","Ja","","47.71","33.17","34.55"
"15","2026-02-17 14:54:00","25","de","744354068","","2026-02-17 13:29:00","2026-02-17 14:48:00","192.168.124.109","619.15","Nein","Therapieoption vorhanden, aber Datenlage dünn","Ja","","36.99","24.06","29.5","Ja","","Ja","","71.08","5.34","26.78","Ja","Gut behandelbar mit diätetischen Maßnahmen","Ja","","66.4","8.8","4.56","Ja","","Ja","","64.24","18.18","22.18","Ich kann diese Frage nicht beantworten","Klinischer Nutzen des NBS fraglich","Ja","","61.64","26.49","36.41","Ich kann diese Frage nicht beantworten","Datenlage noch unvollständig","Nein","Lumasiran-Studien abwarten","59.95","19.44","6.46","Ja","","Ja","Outcome-Daten unter früher Pyridoxin-Therapie sammeln","63.41","5.61","29.06","Ja","","Ja","","82.88","16.5","16.31","Ja","","Ja","","68.61","15.77","33.81","Ich kann diese Frage nicht beantworten","","Ja","","47.1","34.31","8.94","Ja","ERT verfügbar, Frühdiagnose sinnvoll","Ich kann diese Frage nicht beantworten","","30.29","20.77","34.42","Ja","","Ja","","8.01","7.51","26.53","Ja","","Ja","","43.7","15.48","30.73","Ja","Klassisches NBS-Gen, gut etabliert","Ja","","42.96","35.49","20.98","Ja","","Ja","","9.3","31.5","24.04","Nein","Sehr seltene Erkrankung, Datenlage minimal","Ja","","53.35","34.22","5.17","Ja","Seit Jahren erfolgreich im NBS","Ja","","43.62","29.96","24.93","Ja","","Ja","","86.48","26.17","7.39","Ja","","Ja","","48.24","11.85","14.36","Ja","","Ja","","14.17","5.15","33.47","Ja","Klinisch heterogen, schwere neonatale Form selten","Ja","","39.83","16.44","33.52","Ja","","Ja","","27.15","8.74","27.4","Ja","","Ja","","71.37","6.92","32.5","Ich kann diese Frage nicht beantworten","Stark variable Phänotypen erschweren Bewertung","Ja","","51.32","16.37","23.74","Ja","Non-responsive Formen haben schlechten Outcome","Ja","","60.62","30.89","20.91"
"16","2026-02-17 15:49:00","25","de","166514878","","2026-02-17 14:16:00","2026-02-17 15:52:00","192.168.126.185","561.15","Nein","Therapieoption vorhanden, aber Datenlage dünn","Nein","","17.36","5.04","30.31","Ja","","Ja","","66.32","22.24","10.97","Nein","","Ja","","75.2","24.53","35.09","Ja","","Ja","","71.59","11.43","38.93","Nein","","Ja","","29.22","9.52","19.91","Nein","","Nein","","23.02","19.21","12.79","Ja","Gute Behandelbarkeit spricht für NBS","Ja","Outcome-Daten unter früher Pyridoxin-Therapie sammeln","49.04","30.09","36.0","Ja","","Ich kann diese Frage nicht beantworten","NBS-Pilotprojekt könnte Datenlage verbessern","26.78","25.95","16.66","Ja","","Ja","","31.36","34.48","36.41","Nein","Diät schwer einzuhalten","Ich kann diese Frage nicht beantworten","","54.69","13.46","33.69","Ja","","Ja","Studieneinschluss sinnvoll","52.87","11.06","12.27","Ja","Gut etabliertes NBS-Gen","Ja","","87.59","3.34","18.95","Nein","","Ja","","16.74","5.54","12.7","Ja","","Ja","","67.09","22.39","3.38","Nein","Gleiche Erkrankung wie BCKDHA, konsistente Bewertung wichtig","Ja","","43.31","28.1","22.08","Nein","","Ja","","58.83","37.13","25.56","Ja","","Ja","","37.84","12.66","22.62","Ja","","Ja","","82.23","17.05","4.02","Ja","Lebertransplantation einzige kurative Option","Ja","","51.48","25.09","3.14","Ja","","Ja","","81.38","31.48","11.11","Ja","","Ja","","69.41","34.97","9.27","Ja","","Ja","","61.07","9.35","22.11","Ich kann diese Frage nicht beantworten","","Ja","","89.91","32.94","4.91","Ich kann diese Frage nicht beantworten","Stark variable Phänotypen erschweren Bewertung","Ja","Genotyp-basierte Stratifizierung in Studie prüfen","50.65","27.58","34.41","Ja","","Ja","Studiendaten zur frühen Intervention fehlen","35.99","12.42","31.15"
"17","2026-02-18 8:55:00","25","de","508645167","","2026-02-18 7:26:00","2026-02-18 8:37:00","192.168.82.244","608.31","Nein","Frühzeitige Diagnose würde klinisch relevant sein","Ja","Prospektive Studie würde Evidenz stärken","74.07","21.78","12.06","Ich kann diese Frage nicht beantworten","Bereits in vielen Ländern im NBS enthalten","Ja","","23.8","25.01","6.74","Nein","","Ja","","18.89","39.41","20.13","Ja","","Ja","","83.22","28.0","27.49","Nein","Langzeitdaten fehlen noch","Nein","Studien zu Therapieoptionen abwarten","76.31","24.7","22.69","Ja","Lumasiran als neue Therapieoption vielversprechend","Ja","","73.5","27.64","29.6","Ich kann diese Frage nicht beantworten","Gute Behandelbarkeit spricht für NBS","Ja","","18.09","27.32","39.19","Ja","","Ja","","5.97","31.97","26.23","Ja","","Ja","","65.16","22.26","37.37","Ich kann diese Frage nicht beantworten","Neurologische Schäden trotz Therapie häufig","Ich kann diese Frage nicht beantworten","Studiendaten zum Outcome unter NBS notwendig","79.46","18.22","29.22","Ja","","Ja","","30.57","10.41","24.96","Ja","","Ja","","29.36","36.28","16.22","Ja","Bereits in NBS vieler Länder","Ja","","51.25","3.52","30.29","Ja","Klassisches NBS-Gen, gut etabliert","Ja","","21.09","39.94","20.53","Ja","","Ja","","11.3","18.59","29.62","Ich kann diese Frage nicht beantworten","","Nein","Internationale Kollaboration notwendig","31.56","36.42","12.04","Ich kann diese Frage nicht beantworten","","Ja","","6.02","34.83","10.47","Ja","","Ja","","49.73","17.82","11.33","Nein","Outcome trotz Therapie oft schlecht","Ja","","85.82","28.1","8.57","Ja","","Ja","","59.83","5.23","19.43","Ja","","Ja","","68.99","22.96","34.07","Ich kann diese Frage nicht beantworten","Cysteamin-Therapie sehr effektiv wenn früh begonnen","Ja","Frühtherapie-Studien unterstützen NBS-Entscheidung klar","61.01","14.51","35.13","Nein","","Ja","","12.03","19.65","7.83","Ich kann diese Frage nicht beantworten","","Ja","Genotyp-basierte Stratifizierung in Studie prüfen","89.9","35.5","17.49","Ja","","Nein","Studiendaten zur frühen Intervention fehlen","60.14","3.83","7.42"
"18","2026-02-18 9:19:00","25","de","412095398","","2026-02-18 8:12:00","2026-02-18 9:53:00","192.168.215.244","1047.69","Ja","","Ja","","13.49","13.01","8.73","Ja","Sehr gute Behandelbarkeit rechtfertigt Aufnahme","Ja","","51.96","16.66","11.97","Ja","Frühzeitige Diagnose verhindert metabolische Krisen","Ja","","15.77","19.9","29.88","Ja","","Ja","","19.11","36.16","3.32","Ich kann diese Frage nicht beantworten","Therapieansätze in Entwicklung, derzeit noch nicht reif für NBS","Nein","","16.76","33.38","28.61","Nein","Lumasiran als neue Therapieoption vielversprechend","Ja","","29.72","36.12","35.97","Ja","","Ja","","61.89","38.11","23.38","Ja","","Nein","","38.43","28.42","17.87","Ja","","Ja","","57.6","20.62","28.15","Nein","Outcome unter Therapie enttäuschend","Ja","","40.41","4.52","11.36","Ja","Multisystemerkrankung mit gutem Therapieansprechen","Nein","","57.08","20.88","20.66","Ich kann diese Frage nicht beantworten","Klare Behandelbarkeit mit Arginin-Supplementation","Nein","","30.15","39.92","19.1","Ja","","Ja","","78.44","22.72","36.05","Ja","","Ja","","40.1","8.02","39.85","Ja","Gleiche Erkrankung wie BCKDHA, konsistente Bewertung wichtig","Nein","","78.71","37.87","6.26","Ich kann diese Frage nicht beantworten","","Ja","","7.74","38.61","10.27","Ja","","Ja","","35.66","18.56","10.41","Nein","","Nein","","6.76","20.72","30.63","Nein","","Ja","","30.72","15.5","19.35","Ja","","Ja","","13.21","33.2","31.53","Nein","","Ja","","43.1","19.6","5.23","Ja","","Ja","","42.88","21.14","20.92","Ich kann diese Frage nicht beantworten","","Nein","","67.0","34.14","11.76","Ich kann diese Frage nicht beantworten","Stark variable Phänotypen erschweren Bewertung","Ja","","57.17","33.76","17.97","Ja","","Ja","","12.85","31.64","32.02"
"19","2026-02-19 10:15:00","25","de","648374701","","2026-02-19 9:04:00","2026-02-19 10:37:00","192.168.1.193","484.99","Ja","Penetranz unklar, Zurückhaltung geboten","Ja","","56.29","22.7","30.94","Nein","Bereits in vielen Ländern im NBS enthalten","Ja","","7.29","4.73","10.06","Ja","","Ja","","10.68","30.49","24.78","Ja","","Ja","","68.22","29.89","38.65","Ich kann diese Frage nicht beantworten","Therapieansätze in Entwicklung, derzeit noch nicht reif für NBS","Nein","","26.51","11.67","24.76","Nein","Nierentransplantation als Option, Frühdiagnose hilfreich","Ja","Studiendaten zur Frühtherapie fehlen noch","55.2","3.61","12.93","Ja","","Ja","","86.64","10.25","14.73","Ja","","Nein","Kostenevaluation notwendig","80.52","23.18","13.92","Ja","","Ja","","60.04","32.84","15.24","Ja","","Ja","","24.93","13.53","30.53","Nein","Langzeitdaten zur ERT noch begrenzt","Nein","Studieneinschluss sinnvoll","13.46","13.25","17.14","Ich kann diese Frage nicht beantworten","","Ja","","81.11","29.28","14.68","Ja","","Ja","","66.5","6.9","12.02","Ja","","Ja","","46.72","9.61","18.53","Ja","","Ja","","42.69","4.87","13.15","Nein","","Nein","","15.9","37.41","3.12","Ja","","Ja","","11.04","23.71","19.0","Ja","Gut etabliertes NBS-Gen","Ja","","59.19","16.97","3.48","Ich kann diese Frage nicht beantworten","Lebertransplantation einzige kurative Option","Ja","","16.25","6.72","33.56","Ja","Datenlage gut für bestimmte Mutationen","Ja","","31.36","28.73","9.44","Nein","","Ich kann diese Frage nicht beantworten","","32.03","22.9","15.06","Nein","","Ja","","14.36","32.09","27.0","Ja","","Ja","","33.42","16.35","16.44","Ja","","Ja","","14.78","10.26","12.72","Ja","","Ja","","88.85","15.46","10.19"
"20","2026-02-19 11:50:00","25","de","438366171","","2026-02-19 10:02:00","2026-02-19 11:50:00","192.168.43.253","1045.42","Ich kann diese Frage nicht beantworten","Genotyp-Phänotyp-Korrelation unzureichend","Nein","Gentherapie-Studien laufen – Timing der NBS-Einführung wichtig","23.44","8.9","15.0","Ja","","Ja","","76.82","18.37","32.11","Ja","","Ja","","50.53","29.05","28.76","Ja","","Ja","","29.57","13.69","39.41","Nein","Keine kurative Therapie verfügbar","Ja","","72.03","23.02","12.08","Ja","Lumasiran als neue Therapieoption vielversprechend","Ja","","62.64","17.79","27.4","Ja","","Ja","","84.91","9.26","25.45","Ja","","Ja","","62.0","22.53","21.84","Ja","","Ja","","78.4","14.53","19.23","Ich kann diese Frage nicht beantworten","","Ja","","71.69","32.3","25.61","Ich kann diese Frage nicht beantworten","","Nein","","44.56","10.72","18.55","Nein","","Ja","","50.59","27.78","18.49","Ja","Bereits in NBS vieler Länder","Ja","","28.97","6.97","25.79","Ja","","Ja","","40.22","9.1","37.73","Ja","","Nein","","68.95","9.34","27.3","Nein","","Nein","","53.41","29.03","23.91","Ja","","Ja","","89.77","12.46","5.32","Ja","","Ja","","35.33","13.0","10.58","Ja","","Ja","","72.72","18.15","26.86","Ja","","Ja","","37.76","6.9","37.03","Nein","","Ja","","87.9","27.23","10.33","Ja","","Ja","","76.62","19.08","32.66","Ja","","Ja","","6.46","13.09","17.88","Nein","Schwere neonatale Form nicht behandelbar","Ja","","37.97","37.54","38.76","Nein","Non-responsive Formen haben schlechten Outcome","Ja","","10.88","13.78","13.46"
